Hospital
John Ed Chambers Memorial Hospital, INC.
John Ed Chambers Memorial Hospital, INC. was paid $1.29M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 22% of everything it billed.
33Billing provider infoJOHN ED CHAMBERS MEMORIAL HOSPITAL, INC.
DANVILLE, AR 72833
DANVILLE, AR 72833
33aNPI1902842255assigned 06/22/2006
33bProvider typeRural Acute Care Hospital
28Total paid$1.29M
24GClaims143,078
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,913 | $158K | |
| 2019 | 28,471 | $180K | |
| 2020 | 20,269 | $155K | |
| 2021 | 21,266 | $223K | |
| 2022 | 19,138 | $210K | |
| 2023 | 17,881 | $200K | |
| 2024incomplete | 14,140 | $170K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 22% | 26,921 | 21,097 | $291K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 1,938 | 1,557 | $140K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.1% | 12,425 | 6,799 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.9% | 12,917 | 9,822 | $77K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.3% | 2,993 | 2,393 | $69K |
| 80053 | Comprehensive metabolic panel | 5.0% | 8,767 | 6,936 | $65K |
| 80050 | General health panel | 3.0% | 817 | 810 | $39K |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 13,817 | 10,112 | $37K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 2,318 | 1,944 | $35K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.6% | 1,096 | 859 | $34K |
| 80061 | Lipid panel | 2.0% | 3,620 | 2,818 | $26K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 359 | 143 | $24K |
64 more codes
| 87631 | 1.8% | 189 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.8% | 2,235 | $23K |
| 81001 | 1.8% | 5,136 | $23K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 2,389 | $22K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.6% | 2,431 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 3,519 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 1,033 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 6,960 | $16K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.2% | 424 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,558 | $14K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 139 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,388 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,096 | $12K |
| 99283 | Emergency room visit (moderate) | <1% | 393 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,417 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 472 | $12K |
| 87088 | <1% | 1,466 | $9K | |
| 80305 | <1% | 738 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,617 | $8K |
| 83880 | <1% | 683 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,139 | $7K |
| 81025 | <1% | 864 | $6K | |
| 82607 | <1% | 661 | $6K | |
| 84484 | <1% | 623 | $5K | |
| 84436 | <1% | 957 | $4K | |
| 86756 | <1% | 272 | $4K | |
| 80047 | <1% | 411 | $4K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 26 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 114 | $2K |
| 80306 | <1% | 126 | $2K | |
| 81000 | <1% | 579 | $2K | |
| 83690 | <1% | 295 | $2K | |
| 90688 | <1% | 375 | $2K | |
| 92523 | <1% | 16 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,638 | $1K |
| 87077 | <1% | 288 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 782 | $1K |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 1,225 | $1K |
| 84439 | <1% | 210 | $1K | |
| 82150 | <1% | 160 | $1K | |
| 85610 | <1% | 539 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 358 | $1K |
| 87186 | <1% | 268 | $995.84 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $935.16 |
| 71020 | <1% | 69 | $901.00 | |
| 83735 | <1% | 154 | $867.21 | |
| 99284 | Emergency room visit (serious) | <1% | 14 | $831.99 |
| 86677 | <1% | 30 | $393.68 | |
| G0008 | Administration of influenza virus vaccine | <1% | 219 | $355.35 |
| 74018 | <1% | 14 | $203.16 | |
| 85379 | <1% | 40 | $197.16 | |
| 82043 | <1% | 67 | $179.75 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 219 | $94.02 |
| 36416 | <1% | 45 | $52.78 | |
| 85651 | <1% | 23 | $30.42 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 60 | $16.32 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 119 | $1.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 26 | $1.08 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 67 | $0.00 |
| 82947 | 0% | 13 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 42 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 124 | $0.00 |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 0% | 500 | $0.00 |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEEK, MICHAEL (CEO)
| Provider | Location | Paid |
|---|---|---|
| John Ed Chambers Memorial Hospital, INC. | Danville, AR | $593K |
| John Ed Chambers Memorial Hospital, INC | Plainview, AR | $111K |
| John Ed Chambers Memorial Hospital, INC. | Ola, AR | $68K |
| John Ed Chambers Memorial Hospital, INC. | Havana, AR | $30K |
| John Ed Chambers Memorial Hospital, INC | Danville, AR | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.